which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular ... but an observed reduction in cases of heart attacks and strokes failed to reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback